Advertisement
Advertisement

AKBA

AKBA logo

Akebia Therapeutics, Inc.

1.39
USD
Sponsored
+0.01
+0.36%
Feb 06, 15:57 UTC -5
Closed
exchange

After-Market

1.39

0.00
+0.36%

AKBA Earnings Reports

Positive Surprise Ratio

AKBA beat 18 of 40 last estimates.

45%

Next Report

Date of Next Report
Mar 11, 2026
Estimate for Q4 25 (Revenue/ EPS)
$57.32M
/
$0.00
Implied change from Q3 25 (Revenue/ EPS)
-2.46%
/
--
Implied change from Q4 24 (Revenue/ EPS)
+23.28%
/
-100.00%

Akebia Therapeutics, Inc. earnings per share and revenue

On Nov 10, 2025, AKBA reported earnings of 0.00 USD per share (EPS) for Q3 25, beating the estimate of -0.01 USD, resulting in a 100.00% surprise. Revenue reached 58.77 million, compared to an expected 59.40 million, with a -1.07% difference. The market reacted with a -18.14% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 7 analysts forecast an EPS of 0.00 USD, with revenue projected to reach 57.32 million USD, implying an increase of 0.00% EPS, and decrease of -2.46% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
For Q3 2025, Akebia Therapeutics, Inc. reported EPS of $0.00, beating estimates by 100%, and revenue of $58.77M, -1.07% below expectations.
The stock price moved down -18.14%, changed from $2.04 before the earnings release to $1.67 the day after.
The next earning report is scheduled for Mar 11, 2026.
Based on 7 analysts, Akebia Therapeutics, Inc. is expected to report EPS of -- and revenue of $57.32M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement